Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Sharis, Christine M MD (UIA Investigator)
mi
from
Moline, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Sharis, Christine M MD (UIA Investigator)
mi
from
Moline, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Stoffel, Thomas J MD (UIA Investigator)
mi
from
Moline, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Stoffel, Thomas J MD (UIA Investigator)
mi
from
Moline, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Holy Family Medical Center
mi
from
Monmouth, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Holy Family Medical Center
mi
from
Monmouth, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Community Cancer Center Foundation
mi
from
Normal, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Community Cancer Center Foundation
mi
from
Normal, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Pekin Cancer Treatment Center
mi
from
Pekin, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Pekin Cancer Treatment Center
mi
from
Pekin, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Pekin Hospital
mi
from
Pekin, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Proctor Hospital
mi
from
Peoria, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Illinois Valley Hospital
mi
from
Peru, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Illinois Valley Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Margaret's Hospital
mi
from
Spring Valley, IL
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Francis Hospital and Health Centers
mi
from
Beech Grove, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Francis Hospital and Health Centers
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Community Howard Regional Health
mi
from
Kokomo, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Community Howard Regional Health
mi
from
Kokomo, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Indiana University Health La Porte Hospital
mi
from
La Porte, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Indiana University Health La Porte Hospital
mi
from
La Porte, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
South Bend Clinic
mi
from
South Bend, IN
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
South Bend Clinic
mi
from
South Bend, IN
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Constantinou, Costas L MD
mi
from
Bettendorf, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Constantinou, Costas L MD
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cedar Rapids Oncology Association
mi
from
Cedar Rapids, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cedar Rapids Oncology Association
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Hospital
mi
from
Cedar Rapids, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Hospital
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Oncology Associates at Mercy Medical Center
mi
from
Cedar Rapids, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Oncology Associates at Mercy Medical Center
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Capitol
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Capitol
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Iowa Oncology Research Association CCOP
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Iowa Oncology Research Association CCOP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Medical Oncology and Hematology Associates
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Medical Oncology and Hematology Associates
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Medical Center - North Iowa
mi
from
Mason City, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Medical Center - North Iowa
mi
from
Mason City, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Siouxland Hematology Oncology Associates
mi
from
Sioux City, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Siouxland Hematology Oncology Associates
mi
from
Sioux City, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Hospital District Sixth of Harper County
mi
from
Anthony, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Hospital District Sixth of Harper County
mi
from
Anthony, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials